Actinium Pharmaceuticals, ATNM-400, prostate cancer, HER3-targeted radiotherapy, metastatic castration-resistant prostate cancer, radiopharmaceuticals, Phase 1 clinical trial

Vienna, Austria, October 20, 2026 Actinium Pharmaceuticals has announced encouraging initial clinical findings for ATNM-400, an investigational HER3-targeted alpha...